Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Briefs

This article was originally published in The Gray Sheet

Executive Summary

Cohera Medical CEO named AdvaMed Accel chair; Trovagene sacks CEO and CFO over precision medicine dispute; OraSure Technologies appoints Eamonn Hobbs to board; DNA Diagnostics Center names its president and CEO; Lantheus Holdings taps CFO; Omcron gets new president and CEO.

You may also be interested in...



People Briefs: NuVasive, Delcath, Boston Scientific, Silk Road, Si-Bone

NuVasive and Delcath Systems appoint CEOs. Boston Scientific Corp. names senior medical director, rhythm management. Silk Road Medical Inc. appoints executive VP, global sales. Si-Bone taps CFO.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: GSK’s R&D head departs; Bayer’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China’s gene therapy developers rush to the clinic.

Can Novo’s Oral Semaglutide Shake Up Indian Diabetes Segment?

Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?

Topics

Related Companies

UsernamePublicRestriction

Register

MT034646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel